Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
NCT ID: NCT05228314
Last Updated: 2023-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
153 participants
INTERVENTIONAL
2022-05-30
2023-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
NCT04950751
Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
NCT05926440
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
NCT04932824
Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
NCT05188677
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
NCT04672395
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard dose SCB-2020S with CpG/alum adjuvant
Day 1 and 22 standard dose of SCB-2020S with CpG/alum adjuvant
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
CpG/alum adjuvant
CpG/alum adjuvant
Low dose SCB-2020S with low dose squalene based adjuvant
Day 1 and 22 low dose of SCB-2020S with low dose squalene based adjuvant
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Squalene based adjuvant
Squalene based adjuvant
Low dose SCB-2020S with standard dose squalene based adjuvant
Day 1 and 22 low dose of SCB-2020S with standard dose squalene based adjuvant
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Squalene based adjuvant
Squalene based adjuvant
Standard dose SCB-2020S with low dose squalene based adjuvant
Day 1 and 22 standard dose of SCB-2020S with low dose squalene based adjuvant
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Squalene based adjuvant
Squalene based adjuvant
Standard dose SCB-2020S with standard dose squalene based adjuvant
Day 1 and 22 standard dose of SCB-2020S with standard dose squalene based adjuvant
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Squalene based adjuvant
Squalene based adjuvant
Standard dose SCB-2019 with CpG/alum adjuvant
Day 1 and 22 standard dose of SCB-20219 with standard CpG/alum adjuvant
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
CpG/alum adjuvant
CpG/alum adjuvant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candidate vaccine, SCB-2020S
a recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine for COVID-19
Candidate vaccine, SCB-2019
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
Squalene based adjuvant
Squalene based adjuvant
CpG/alum adjuvant
CpG/alum adjuvant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests and other study procedures
* Individuals are willing and able to give an informed consent, prior to screening
* Healthy participants or participants with pre-existing medical conditions who are in a stable medical condition.
* Female participants of childbearing potential may be enrolled in the study, if the participant has practiced highly effective method of contraception for 30 days prior to vaccination and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception for 3 months after the last vaccination
* Male participants must agree to employ acceptable contraception from the day of the first dose of the study vaccine until 6 months after the last dose of the study vaccine and also refrain from donating sperm during this period
Exclusion Criteria
* Body mass index at screening \>30 kg/m2
* Individuals with laboratory-confirmed SARS-CoV-2 infection \[as defined by reverse transcriptase polymerase chain reaction (RT-PCR) assay or Rapid COVID Antigen Test or an equivalent\] at the screening visit or with known history of COVID-19 within 6 months prior to Day 1
* Individuals who have received an investigational or authorized COVID-19 vaccine within 6 months prior to Day 1, or plan to receive COVID-19 vaccine during the study period
* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease \[e.g., malignancy, human immunodeficiency virus (HIV) infection\] or immunosuppressive/cytotoxic therapy (e.g., systemic corticosteroids, medications used for cancer chemotherapy, organ transplantation or to treat autoimmune disorders) within 3 months prior to Day 1.
* Individuals with any progressive unstable or uncontrolled clinical conditions
* Individuals who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or during the study period
* Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction, e.g., anaphylaxis to any components of the study vaccines
* Individuals who have a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix which have been cured, or other malignancies with minimal risk of recurrence).
* Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study
* Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 28 days after the second vaccination
* Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate i.m. injection
* Individuals who have received treatment with rituximab or any other anti-CD20 monoclonal antibodies within 9 months prior to Day 1 or planned during the study period
* Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the study period
* Individuals with positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening
* Individuals with safety laboratory test results (hematology, biochemistry, and coagulation) with a toxicity score of Grade ≥2 at Screening.
* The participant has a reported or documented history of alcohol abuse or drug addiction (excluding nonprescription health supplements and herbal remedies) within 1 year before the planned day of dose administration
* The participant has a positive test result for drugs of abuse at Screening
* Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clover Biopharmaceuticals AUS Pty
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Josha Research
Bloemfontein, , South Africa
Global Clinical Trials (Pty) Ltd
Pretoria, , South Africa
Wits Vaccines and Infectious Diseases Analytics (VIDA) Research Unit
Soweto, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLO-SCB-2020S-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.